Free Trial

ZyVersa Therapeutics (ZVSA) Competitors

ZyVersa Therapeutics logo
$0.67 -0.03 (-4.00%)
Closing price 07/3/2025 03:58 PM Eastern
Extended Trading
$0.67 0.00 (0.00%)
As of 07/3/2025 04:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

ZVSA vs. EYEN, ALVR, ATHA, IBIO, EQ, CTXR, BGXX, PHIO, BCDA, and PHXM

Should you be buying ZyVersa Therapeutics stock or one of its competitors? The main competitors of ZyVersa Therapeutics include Eyenovia (EYEN), AlloVir (ALVR), Athira Pharma (ATHA), iBio (IBIO), Equillium (EQ), Citius Pharmaceuticals (CTXR), Bright Green (BGXX), Phio Pharmaceuticals (PHIO), BioCardia (BCDA), and PHAXIAM Therapeutics (PHXM). These companies are all part of the "pharmaceutical products" industry.

ZyVersa Therapeutics vs. Its Competitors

ZyVersa Therapeutics (NASDAQ:ZVSA) and Eyenovia (NASDAQ:EYEN) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their media sentiment, risk, earnings, institutional ownership, dividends, analyst recommendations, valuation and profitability.

ZyVersa Therapeutics has higher earnings, but lower revenue than Eyenovia.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
ZyVersa TherapeuticsN/AN/A-$9.41MN/AN/A
Eyenovia$60K766.08-$49.82M-$58.40-0.27

ZyVersa Therapeutics has a beta of 0.82, indicating that its stock price is 18% less volatile than the S&P 500. Comparatively, Eyenovia has a beta of 2.47, indicating that its stock price is 147% more volatile than the S&P 500.

In the previous week, Eyenovia had 6 more articles in the media than ZyVersa Therapeutics. MarketBeat recorded 6 mentions for Eyenovia and 0 mentions for ZyVersa Therapeutics. Eyenovia's average media sentiment score of 0.34 beat ZyVersa Therapeutics' score of 0.00 indicating that Eyenovia is being referred to more favorably in the news media.

Company Overall Sentiment
ZyVersa Therapeutics Neutral
Eyenovia Neutral

Eyenovia has a consensus price target of $2.00, suggesting a potential downside of 87.47%. Given Eyenovia's stronger consensus rating and higher probable upside, analysts plainly believe Eyenovia is more favorable than ZyVersa Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
ZyVersa Therapeutics
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
Eyenovia
0 Sell rating(s)
4 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
2.00

ZyVersa Therapeutics has a net margin of 0.00% compared to Eyenovia's net margin of -62,238.41%. Eyenovia's return on equity of 0.00% beat ZyVersa Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
ZyVersa TherapeuticsN/A -109.54% -43.95%
Eyenovia -62,238.41%N/A -316.90%

3.9% of ZyVersa Therapeutics shares are held by institutional investors. Comparatively, 25.8% of Eyenovia shares are held by institutional investors. 0.2% of ZyVersa Therapeutics shares are held by insiders. Comparatively, 7.1% of Eyenovia shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Summary

Eyenovia beats ZyVersa Therapeutics on 9 of the 12 factors compared between the two stocks.

Get ZyVersa Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for ZVSA and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ZVSA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

ZVSA vs. The Competition

MetricZyVersa TherapeuticsMED IndustryMedical SectorNASDAQ Exchange
Market Cap$3.20M$2.89B$5.56B$9.04B
Dividend YieldN/A2.44%5.24%4.01%
P/E RatioN/A21.7127.6620.25
Price / SalesN/A281.81415.41118.18
Price / CashN/A42.7336.8958.07
Price / Book0.207.518.035.67
Net Income-$9.41M-$55.14M$3.18B$249.21M
7 Day Performance-5.67%4.61%2.93%3.27%
1 Month Performance4.15%4.72%3.75%5.55%
1 Year Performance-81.69%5.92%35.20%21.08%

ZyVersa Therapeutics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
ZVSA
ZyVersa Therapeutics
0.59 of 5 stars
$0.67
-4.0%
N/A-81.4%$3.20MN/A0.002
EYEN
Eyenovia
2.6378 of 5 stars
$5.48
+30.2%
$2.00
-63.5%
-74.0%$12.14M$60K-0.0940Analyst Upgrade
High Trading Volume
ALVR
AlloVir
N/A$2.40
-6.6%
N/A-85.2%$12.10MN/A-0.12110Gap Up
High Trading Volume
ATHA
Athira Pharma
2.7421 of 5 stars
$0.30
-2.3%
$11.25
+3,700.7%
-87.1%$11.83MN/A-0.1440Gap Down
IBIO
iBio
2.0615 of 5 stars
$0.71
-7.6%
$4.30
+503.6%
-63.0%$11.77M$375K0.00100High Trading Volume
EQ
Equillium
1.8301 of 5 stars
$0.29
-11.3%
$3.00
+934.5%
-50.6%$11.68M$41.10M-0.7440Gap Down
CTXR
Citius Pharmaceuticals
2.1615 of 5 stars
$1.03
-4.6%
$54.50
+5,191.3%
-81.9%$11.48MN/A0.0020High Trading Volume
BGXX
Bright Green
N/AN/AN/AN/A$11.47MN/A-1.002Gap Down
PHIO
Phio Pharmaceuticals
2.2118 of 5 stars
$2.18
-4.0%
$14.00
+542.2%
-53.4%$10.87MN/A-0.2010
BCDA
BioCardia
3.9913 of 5 stars
$2.02
-2.9%
$25.00
+1,137.6%
-29.4%$10.77M$3K-0.8740News Coverage
Positive News
Insider Trade
Gap Up
PHXM
PHAXIAM Therapeutics
N/A$3.10
flat
N/AN/A$10.58M$32.66M0.0049

Related Companies and Tools


This page (NASDAQ:ZVSA) was last updated on 7/5/2025 by MarketBeat.com Staff
From Our Partners